Sushil Dhakal

  • Post doc; PhD
  • +47 46 37 49 78

I have a background in cancer immunology, translational oncology, and immunotherapy-based drug combinations. My expertise lies within the study of the tumor–immune microenvironment, in vivo cancer models, and molecular techniques such as RNA sequencing, CRISPR–Cas9 genome editing, and flow cytometry. In the Breast Tumor Evolution Group, my research focuses on elucidating the molecular mechanisms by which the receptor tyrosine kinase FGFR1 regulates innate immune signaling and DNA sensing through the cGAS–STING pathway, and on determining how FGFR1 inhibition influences anti-tumor immunity in immunologically cold breast cancer.

 

Publications 2025

Dhakal S, Siraji MI, Grøndal SM, Skarsten GN, Moutoussamy EE, Gausdal G, Lorens JB, Bougnaud S (2025)
AXL kinase inhibition promotes cytosolic DNA sensor cGAS activity and sensitizes poorly immunogenic tumors to chemo-immunotherapy
Mol Cancer Ther (in press)
DOI 10.1158/1535-7163.MCT-24-0440, PubMed 41263056

Publications 2020

Engelsen AST, Wnuk-Lipinska K, Bougnaud S, Pelissier Vatter FA, Tiron C, Villadsen R, Miyano M, Lotsberg ML, Madeleine N, Panahandeh P, Dhakal S, Tan TZ, Peters SD, Grøndal S, Aziz SM, Nord S, Herfindal L, Stampfer MR, Sørlie T, Brekken RA, Straume O, Halberg N, Gausdal G, Thiery JP, Akslen LA et al. (2020)
AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer
iScience, 23 (11), 101649
DOI 10.1016/j.isci.2020.101649, PubMed 33103086

Scroll to top